PCI drug delivery technology enhances effect of anti-cancer drug
In a recent article, entitled "Site-specific drug delivery by photochemical internalization enhances the antitumor effect of bleomycin" Kristian Berg's group demonstrate that PCI can significantly improve the curative effect of the anti-cancer drug bleomycin in animal models.
The findings were published in December 1st issue the acknowledged cancer journal Clinical Cancer Research (impact factor 5,62). The article shows that by employing PCI, fully curative effects can be achieved with a dose of bleomycin that in itself is inefficient in inducing tumour cure.
The findings were published in December 1st issue the acknowledged cancer journal Clinical Cancer Research (impact factor 5,62). The article shows that by employing PCI, fully curative effects can be achieved with a dose of bleomycin that in itself is inefficient in inducing tumour cure.
The article demonstrates the potential of the PCI technology to make tumour treatment more efficient and specific, potentially making it possible to reduce the required doses of anti-cancer drugs to a level where side effects may be substantially reduced, while the therapeutic effects are improved.
Kjetil Hestdal, President and CEO of PhotoCure, says: "This study is an important milestone in the development of PCI Biotech's technology and strongly supports the uniqueness of this drug delivery technology."
Recently, the first PCI-mediated gene delivery in vivo was published in Nature Materials
Read about it here.
About PhotoCure ASA:
PhotoCure ASA is, together with its subsidiary PCI Biotech AS, developing a proprietary technology for site-specific drug delivery called photochemical internalisation (PCI). The PCI technology uses light to activate drug delivery and can be used to enhance the effect of drugs by targeted illumination of specific sites of the body (e.g.in tumours). The technology has a potential to improve the effect both of existing drugs and of emerging treatments such as gene therapy and other therapies based on biotechnological principles.
PhotoCure ASA is a Norwegian pharmaceutical company listed on Oslo Stock Exchange. The company develops and sells pharmaceuticals and medical devices based on proprietary photodynamic technologies, targeting key dermatology and oncology markets.
PhotoCure has two products with sales and marketing approvals: Metvix®, for the treatment of skin cancer (basal cell carcinoma) and pre-cancerous skin lesions (actinic keratosis), and Hexvix®, for the detection of bladder cancer. Both products are based on the same photodynamic technology, combining the drug known as a photosensitiser with a light source that activates the photosensitiser. PhotoCure is currently testing both products for new indications and aims to develop a pipeline of follow-on products and technologies.
PCI Biotech AS is a subsidiary of PhotoCure, established in 2000 to commercialise its proprietary technology, photochemical internalisation (PCI). PCI is a technology for light-directed drug delivery and was developed to introduce therapeutic molecules in a biologically active form specifically into diseased cells. PCI Biotech is developing a new proprietary photosensitiser specially designed for use in the PCI technology.
Kristian Berg's group
Kjetil Hestdal, President and CEO of PhotoCure, says: "This study is an important milestone in the development of PCI Biotech's technology and strongly supports the uniqueness of this drug delivery technology."
Recently, the first PCI-mediated gene delivery in vivo was published in Nature Materials
Read about it here.
About PhotoCure ASA:
PhotoCure ASA is, together with its subsidiary PCI Biotech AS, developing a proprietary technology for site-specific drug delivery called photochemical internalisation (PCI). The PCI technology uses light to activate drug delivery and can be used to enhance the effect of drugs by targeted illumination of specific sites of the body (e.g.in tumours). The technology has a potential to improve the effect both of existing drugs and of emerging treatments such as gene therapy and other therapies based on biotechnological principles.
PhotoCure ASA is a Norwegian pharmaceutical company listed on Oslo Stock Exchange. The company develops and sells pharmaceuticals and medical devices based on proprietary photodynamic technologies, targeting key dermatology and oncology markets.
PhotoCure has two products with sales and marketing approvals: Metvix®, for the treatment of skin cancer (basal cell carcinoma) and pre-cancerous skin lesions (actinic keratosis), and Hexvix®, for the detection of bladder cancer. Both products are based on the same photodynamic technology, combining the drug known as a photosensitiser with a light source that activates the photosensitiser. PhotoCure is currently testing both products for new indications and aims to develop a pipeline of follow-on products and technologies.
PCI Biotech AS is a subsidiary of PhotoCure, established in 2000 to commercialise its proprietary technology, photochemical internalisation (PCI). PCI is a technology for light-directed drug delivery and was developed to introduce therapeutic molecules in a biologically active form specifically into diseased cells. PCI Biotech is developing a new proprietary photosensitiser specially designed for use in the PCI technology.
Kristian Berg's group